Search This Blog

Wednesday, January 8, 2020

Collegium sees Xtampza sales as high as $160M this year

Collegium Pharmaceutical (NASDAQ:COLL) provides its 2020 outlook.
Xtampza ER (oxycodone) sales: $150M – 160M.
Nucynta (tapentadol) franchise sales: $170M – 180M.
Operating expenses: $130M – 140M.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)